<DOC>
	<DOCNO>NCT01671696</DOCNO>
	<brief_summary>The main hypothesis test image serologic biomarkers apoptosis progressive extracellular matrix remodel precede echocardiographic index systolic diastolic function among childhood cancer survivor treat anthracyclines thus allow evaluation new therapy prevent manage heart failure patient .</brief_summary>
	<brief_title>Defining Late Onset Occult Asymptomatic Cardiotoxicity Childhood Cancer Survivors Exposed Anthracycline Therapy</brief_title>
	<detailed_description>Part A : Patients receive high dose anthracyclines complete chemotherapy minimum 2 year still remission gather information previous heart disease , radiation dose heart , bone marrow transplant , age treatment , gender , elevation serum cardiac troponin-T N-terminal pro-brain natriuretic peptide measurement anthracycline therapy , systolic dysfunction congestive heart failure anthracycline therapy . Participants Cardiac MRI ( CMRI ) , echo collection serum measurement biomarkers inflammation ( C Reactive Protein ( CRP ) , TNF-α , myocyte injury ( Cardiac troponin ( cTn ) , extracellular matrix remodeling , ( Matrix Metalloproteinases ( MMP ) , Tissue inhibitor metalloproteinases ( TIMPs ) , C terminal propeptide type I procollagen ( PICP ) , C terminal telopeptide collagen type I ( CITP ) , Bone Alkaline Phosphatase , apoptosis ( Caspase-3 P17 peptide ) , ventricular derive B-type natriuretic peptide ( BNP ) study . Part A complete . Part B : For patient enrolled part A another CMRI validate CMRI finding study progression cardiomyopathy overtime compare CMRI derive image parameter first second subject visit . Results standard care echo post-processed include parameter subject ' previous research echo take place 2 year ago comparison . Subjects blood draw ( 3mL ) DNA RNA analysis . Part B complete . Part C : Will include additional 60 patient receive low dose anthracycline therapy ( &lt; 300 mg/m2 ) also identify cardio-oncology registry . These patient undergo CMRI , study echo , blood sample collection serum measurement biomarkers inflammation , microRNA caspase . Matrix/Fibrosis pathway : Plasma level soluble type MMPs , 4 TIMPs ; Inflammatory domain : cytokine ( TNFα , interleukins , interferon gamma ( IFNG ) , TGF β2 , TGF βII ) ) , cytokine receptor ( sTNF RI , sTNF RII , sSt2 , sgp130 , siL1RII/sCD121b , siL-2Rα/CD25 , siL-4R , siL- 6R , Endoglin ) , acute phase protein : CRP ; Signaling pathway : growth factor ( GDP-15 , GCSF , VEGF , sVEGFR2 TGFβ1 , IGF-1 ; Cell viability/growth domain : Indices myocyte death apoptosis ( Caspase-3 P17 peptide ) , myocyte injury ( cardiac troponin T ( cTnT ) ; Neuro-hormones : NTproBNP ; . All measurement do duplicate use internally validate calibrate multiplex suspension array . Results standard care echo post-processed include parameter original 60 subject ' previous research echocardiogram comparison purpose . All subject recruit serve either `` case '' ( cardiotoxicity ) control , free cardiotoxicity . Currently enrol part C patient receive low dose anthracyclines . Cardiotoxicity overall group define global systolic dysfunction ( indicated ejection fraction &lt; 2SD normal ( Z score &lt; -2 ) , decrease global circumferential longitudinal strain magnitude less 2SD normal . CMRI consider standard care assessment cardiomyopathy . Based proven utility CMRI screen tool cardiomyopathy , CMRI study perform standard care assessment global regional myocardial function cancer survivor . T1 pulse sequence estimation native T1 ECV continually develop refine , require validation prior clinical application . These sequence still consider part research . STATISTICAL ANALYSIS Part A. CMRI parameter correlate echo parameter systolic diastolic function . Data peak circumferential strain compare publish historic normative data . T1 relaxation value compare group age match control normal SF exposure anthracyclines . Results express mean SD continuous data percentage number categorical data . Subjects classify 3 group detail previously . Differences mean group expose control normally distribute data assess analysis variance . For skewed data , Mann-Whitney U test performed . Image quality score patient average correspond T1 map . Mean segmental T1 ventricular myocardial peak circumferential strain value standard deviation calculate . The literature show T1 value subject mild systematic heart rate dependency patient 's height weight impact T1 value . To find correct potential confounding factor , relationship T1 heart rate , height , weight investigate use linear regression analysis section data . In addition , relationship T1 mapping-derived relaxation time , leave ventricular myocardial peak circumference strain echocardiography parameter systolic diastolic function investigate use linear regression analysis section data . All statistical analysis perform SAS 9.2 . All test two tail , P &lt; .05 consider indicate significant difference . Interobserver intraobserver variability HARP strain perform use pair test report mean difference 95 % confidence interval . Serum level MMP-1 , MMP-2 , MMP-9 MMP-1/TIMP ratio , PICP , CITP , Bone Alkaline Phosphatase Caspase-3 P17 peptide measure indicator extracellular matrix remodel apoptosis , respectively compare CMRI echocardiographic parameter systolic diastolic function . Serum level cleave p17 fragment ( p17 ) Caspase-3 , end effector caspase apoptosis , compare publish normative data group 167 healthy subject 68 . Circulating level MMP-1 , MMP-2 , MMP-9 TIMP-1 compare publish historic healthy control 69 Serum biomarkers N-terminal pro-BNP ( NT-pro-BNP ) Cardiac troponin also obtain give know association cardiac dysfunction . Biomarkers statistical analysis result express mean SD continuous data percentage number categorical data . Subjects classify three group detail previously . Differences mean group normally distribute data assess analysis variance . For skewed data , Mann-Whitney U test performed . The relationship level Troponin , Caspase-3 P17 peptide , MMPS , TIMPs , PICP , CITP , Bone Alkaline Phosphatase , CRP , CK-MB , echo parameter systolic diastolic function investigate use linear regression analysis section data . All statistical analysis perform SAS 9.2 . All test two tail , P &lt; .05 consider indicate significant difference . The interdisciplinary nature potential bedside bench translational research position u obtain pilot data base project change patient cohort . For example , test whether serum P17 level patient group ( group 1-3 ) high healthy control . However , possible late group ( Group 2 3 ) show rise P17 level . Similarly , late group may show change serum MMPs T1 relaxation time . If change small detect give sample size , focus parameter exhibit large difference vs. healthy control . This also guide u design future study . The change MMPs may reflect presence diastolic vs. systolic dysfunction early vs. late group . For example , possible early group ( Group 1 ) exhibit diastolic problem , manifest reduce MMP-1/TIMP-1 ratio . When significant systolic dysfunction ensues , ratio may reverse . Part B : All CMRI image biomarkers cardiotoxicity demonstrate baseline pilot study compare among first second study visit among high dose ( ≥240 mg/m2 ) subject . Frequencies percents patient exhibit phenotype cardiotoxicity measure cMRI calculate study visit . If frequencies/percents great second visit compare first , use cMRI indicate anthracycline induce cardiotoxicity validate . Specific Aim 2 : All CMR image parameter athracycline induce cardiomyopathy compare first second study visit among high dose ( ≥240 mg/m2 ) subject . All CMR volumetric parameter include volume , mass , measurement end systolic fiber stress well measurement global regional myocardial function , T1 map ECV compare two study visit use paired t-tests , p &lt; 0.05 used indicate statistically significant difference . Part C : Specific Aim 1 : The objective aim test hypothesis CMR image biomarkers AIC le frequent among subject expose low dose anthracyclines . The proportion subject possess anthracycline-induced cardiotoxicity phenotype high low dose group compare use Fisher 's exact test . P &lt; 0.05 used indicate statistically significant difference . Specific Aim 2 : This aim tell hypothesis elevation biomarkers inflammation , myocyte injury , extracellular matrix remodel apoptosis le prevalent survivor childhood cancer expose low-dose anthracyclines , reflect low level serum CRP , high sensitivity troponin , MMPs Caspase-3 P17 level . The objective characterize change serum level marker extracellular matrix remodel apoptosis patient various interval anthracycline chemotherapy . Serum level MMP-1 , MMP-2 , MMP-9 MMP-1/TIMP ratio , PICP , CITP , Bone Alkaline Phosphatase Caspase-3 P17 peptide measure indicator extracellular matrix remodel apoptosis , respectively compare CMRI echocardiographic parameter systolic diastolic function . Serum level cleave p17 fragment ( p17 ) Caspase-3 , end effector caspase apoptosis , compare publish normative data group 167 healthy subject . Circulating level MMP-1 , MMP-2 , MMP-9 TIMP-1 compare normal control . Serum biomarkers N-terminal pro-BNP ( NT-pro-BNP ) Cardiac troponin also obtain give know association cardiac dysfunction . DNA RNA analysis collect future analysis Jackson Lab bioinformatics core unit , analyze base result parallel murine model cardiotoxicity .</detailed_description>
	<mesh_term>Cardiovascular Diseases</mesh_term>
	<mesh_term>Cardiotoxicity</mesh_term>
	<criteria>Childhood cancer survivor late effect clinic continuous , complete remission chemotherapy minimum 2 year . Age &gt; 9 year age Contraindications CMRI Relapse cancer Pregnancy</criteria>
	<gender>All</gender>
	<minimum_age>9 Years</minimum_age>
	<maximum_age>35 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>